RARE Quote, Financials, Valuation and Earnings

Insulet has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of 16.85%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Insulet's return on equity of 43.11%.

Ultragenyx Pharmaceutical has a consensus price target of $92.70, signalling upside risk potential of 198.46%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 26.67%. Given that Ultragenyx Pharmaceutical has higher upside potential than Insulet, analysts believe Ultragenyx Pharmaceutical is more attractive than Insulet.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are smaller than Insulet quarterly revenues of $597.5M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Insulet's net income of $100.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Insulet's PE ratio is 42.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.02x versus 8.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of 24.22%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Ultragenyx Pharmaceutical has a consensus price target of $92.70, signalling upside risk potential of 198.46%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $904.00 which suggests that it could grow by 62.87%. Given that Ultragenyx Pharmaceutical has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Regeneron Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.02x versus 4.51x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -9.24%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Ultragenyx Pharmaceutical has a consensus price target of $92.70, signalling upside risk potential of 198.46%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 205.96%. Given that Vanda Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vanda Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.02x versus 1.21x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics has a net margin of -80.9% compared to Ultragenyx Pharmaceutical's net margin of -6020.94%. Ultragenyx Pharmaceutical's return on equity of -194.36% beat Vistagen Therapeutics's return on equity of -45.8%.

Ultragenyx Pharmaceutical has a consensus price target of $92.70, signalling upside risk potential of 198.46%. On the other hand Vistagen Therapeutics has an analysts' consensus of $13.00 which suggests that it could grow by 540.39%. Given that Vistagen Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vistagen Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.607, which suggesting that the stock is 39.255% less volatile than S&P 500. In comparison Vistagen Therapeutics has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.775%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Vistagen Therapeutics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $164.9M, which are larger than Vistagen Therapeutics quarterly revenues of $234K. Ultragenyx Pharmaceutical's net income of -$133.4M is lower than Vistagen Therapeutics's net income of -$14.1M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Vistagen Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.02x versus 86.50x for Vistagen Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.